CD19 and diffuse large B-cell lymphoma: Axicabtagene ciloleucel (axi-cel)—a CD19-targeting product which differs from the other approved CAR T-cell products for its CD28 co-stimulatory intracellular domain—was approved for both DLBCL and FL patients.